963-RAS-GTP Inhibition in KRAS Mutant Cholangiocarcinoma

Paper Talk · May 13, 2026 · 22m

This study examines the therapeutic efficacy of RAS(ON) multi-selective inhibitors—specifically daraxonrasib and the compound RMC-7977—in treating KRAS-mutant cholangiocarcinoma (CCA). Through extensive testing in cell-derived and patient-derived models, researchers demonstrated that these inhibitors significantly suppress tumor growth and improve survival rates by targeting the active, GTP-bound state of RAS. The findings highlight that RAS pathway reactivation, through mechanisms like gene amplification and MYC overexpression, serves as the primary driver of drug resistance. Furthermore…